CFDE Data Portal | Search MTND6P4

	Label	Description
	MTND6P4 Gene (Entity type)	ENSG00000249119 - MT-ND6 pseudogene 4
	GSE128076 doxycycline HEK293 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE130246 enzalutamide UM 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE121425 GSE121426 LSD1 inhibition SET-2 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239688 canagliflozin 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE229973 cisplatin 4 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE183606 rutaecarpine 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE199107 tryptophan 4 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE225869 temozolomide 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE225869 CD44 knockdown 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

MTND6P4

ENSG00000249119 - MT-ND6 pseudogene 4

GSE128076 doxycycline HEK293 1 v 3 human dn

A Gene Set from LINCS

GSE130246 enzalutamide UM 1 v 3 human dn

A Gene Set from LINCS

GSE121425 GSE121426 LSD1 inhibition SET-2 2 v 0 human up

A Gene Set from LINCS

GSE239688 canagliflozin 2 v 1 human up

A Gene Set from LINCS

GSE229973 cisplatin 4 v 5 human dn

A Gene Set from LINCS

GSE183606 rutaecarpine 1 v 0 human up

A Gene Set from LINCS

GSE199107 tryptophan 4 v 5 human up

A Gene Set from LINCS

GSE225869 temozolomide 1 v 0 human up

A Gene Set from LINCS

GSE225869 CD44 knockdown 1 v 0 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.